Biocytogen Pharmaceuticals Expands Bispecific Antibody-Drug Conjugate Collaboration With Acepodia
I'm PortAI, I can summarize articles.
Biocytogen Pharmaceuticals Beijing Co. Ltd. has expanded its collaboration with Acepodia Inc. through an option and license agreement. This partnership focuses on developing dual-payload bispecific antibody-drug conjugates (BsAD2Cs) using Biocytogen’s RenLite® platform and Acepodia’s AD2C technology. The agreement allows Acepodia to obtain an exclusive worldwide license for these bispecific ADC programs, with decisions guided by ongoing research and internal review criteria.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments